MD480Z - Metoda de tratament al colitei ulceroase nespecifice acute - Google Patents
Metoda de tratament al colitei ulceroase nespecifice acute Download PDFInfo
- Publication number
- MD480Z MD480Z MDS20110128A MDS20110128A MD480Z MD 480 Z MD480 Z MD 480Z MD S20110128 A MDS20110128 A MD S20110128A MD S20110128 A MDS20110128 A MD S20110128A MD 480 Z MD480 Z MD 480Z
- Authority
- MD
- Moldova
- Prior art keywords
- day
- administered
- aminosalicylic acid
- solution
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000001154 acute effect Effects 0.000 title claims abstract description 4
- 208000025865 Ulcer Diseases 0.000 title abstract description 4
- 206010009887 colitis Diseases 0.000 title abstract 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960004963 mesalazine Drugs 0.000 claims abstract description 27
- 210000001072 colon Anatomy 0.000 claims abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 10
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 7
- 239000006260 foam Substances 0.000 claims abstract description 7
- 102000009027 Albumins Human genes 0.000 claims abstract description 6
- 108010088751 Albumins Proteins 0.000 claims abstract description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 6
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 238000001784 detoxification Methods 0.000 claims abstract description 4
- -1 1-ethylpyrrolidin-2-yl Chemical group 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 19
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 19
- 239000007920 enema Substances 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 6
- 229940095399 enema Drugs 0.000 claims description 5
- 229940079360 enema for constipation Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000008279 sol Substances 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 4
- 241000792859 Enema Species 0.000 description 3
- 229940072224 asacol Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000005353 urine analysis Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 101100010166 Mus musculus Dok3 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- YFUATOCFMCWUEH-UHFFFAOYSA-N chembl2105427 Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N=NC=2C=C(C(O)=CC=2)C(O)=O)C=C1 YFUATOCFMCWUEH-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 208000017048 proctosigmoiditis Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000012794 white bread Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110128A MD480Z (ro) | 2011-07-07 | 2011-07-07 | Metoda de tratament al colitei ulceroase nespecifice acute |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110128A MD480Z (ro) | 2011-07-07 | 2011-07-07 | Metoda de tratament al colitei ulceroase nespecifice acute |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD480Y MD480Y (en) | 2012-02-29 |
| MD480Z5 MD480Z5 (ro) | 2012-09-30 |
| MD480Z true MD480Z (ro) | 2012-09-30 |
Family
ID=45815378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20110128A MD480Z (ro) | 2011-07-07 | 2011-07-07 | Metoda de tratament al colitei ulceroase nespecifice acute |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD480Z (mo) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8903914D0 (sv) * | 1989-11-22 | 1989-11-22 | Draco Ab | Oral composition for the treatment of inflammatory bowel diseases |
| RU2056849C1 (ru) * | 1992-03-03 | 1996-03-27 | Кириллов Владимир Анатольевич | Способ лечения неспецифического язвенного колита |
| EP0806204A4 (en) * | 1993-12-01 | 2001-06-27 | Sankyo Co | Inflammatory cytokine production inhibitor containing polyprenyl derivative as active ingredient |
| PT1074268E (pt) * | 1998-03-17 | 2008-02-28 | Chugai Pharmaceutical Co Ltd | Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6 |
| RU2200007C2 (ru) * | 1999-03-05 | 2003-03-10 | Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра СО РАМН | Способ лечения больных неспецифическим язвенным колитом |
| JP4210454B2 (ja) * | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| RU2165758C1 (ru) * | 2000-09-04 | 2001-04-27 | Андрей Эдуардович Дорофеев | Способ лечения язвенного колита |
| RU2318537C2 (ru) * | 2001-04-06 | 2008-03-10 | Юниверсити Оф Бристоль | Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам |
| MXPA04003266A (es) * | 2001-10-05 | 2004-07-08 | Combinatorx Inc | Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios. |
| RU2215546C1 (ru) * | 2002-03-29 | 2003-11-10 | Алтайский государственный медицинский университет | Способ лечения неспецифического язвенного колита |
| ATE477268T1 (de) * | 2003-01-28 | 2010-08-15 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur behandlung von magen-darm- störungen |
| US20070173461A1 (en) * | 2004-02-03 | 2007-07-26 | Nippon Shinyaku Co., Ltd. | Glycoside prodrug of 5- aminosalicylic acid |
| PT1776336E (pt) * | 2004-03-23 | 2009-12-18 | Dompe Spa | Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm |
| DK1747008T3 (en) * | 2004-04-28 | 2015-03-30 | Nutrition Science Partners Ltd | Crude extract FROM Andrographis paniculata |
| RU2328298C1 (ru) * | 2007-03-30 | 2008-07-10 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) | Способ лечения неспецифического язвенного колита |
| RU2394571C1 (ru) * | 2009-05-14 | 2010-07-20 | Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы | Способ лечения воспалительных заболеваний кишечника |
| RU2419443C1 (ru) * | 2009-12-08 | 2011-05-27 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ лечения больных язвенным колитом |
| RU2460554C1 (ru) * | 2011-01-12 | 2012-09-10 | Петр Леонидович Щербаков | Способ терапии язвенного колита и болезни крона |
-
2011
- 2011-07-07 MD MDS20110128A patent/MD480Z/ro not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD480Z5 (ro) | 2012-09-30 |
| MD480Y (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3915566B1 (en) | Composition for preventing or treating inflammatory bowel disease, containing, as active ingredient, taurodeoxycholic acid or pharmaceutically acceptable salt thereof | |
| Lan et al. | L-arginine ameliorates lipopolysaccharide-induced intestinal inflammation through inhibiting the TLR4/NF-κB and MAPK pathways and stimulating β-defensin expression in vivo and in vitro | |
| Stolman et al. | Pyoderma gangrenosum and rheumatoid arthritis | |
| Katano et al. | Neutrophil‐mediated tumor cell destruction in cancer ascites | |
| US9913867B2 (en) | Composition comprising extract of mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis | |
| US20120157417A1 (en) | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | |
| CN113304133B (zh) | 贝壳杉烷类化合物在制备预防和治疗炎症性肠病的药物中的应用 | |
| US10183040B2 (en) | Method for regulation of lipid metabolism | |
| Chebion et al. | Drug-induced nephrolithiasis and crystalluria: the particular case of the sulfasalazine derivatives | |
| CN116514911A (zh) | 一种多肽及其在制备用于治疗慢性荨麻疹药物中的用途 | |
| CN111228281A (zh) | 甘草酸二铵的新用途 | |
| Uttamani et al. | Therapeutic Modalities in the management of COVID-19: A worldwide landscape | |
| CN116098886A (zh) | 一种药物组合物及其应用 | |
| TWI432203B (zh) | 以羊毛固醇及茯苓萃取物治療惡病質的用途 | |
| WO2021012789A1 (zh) | 含溶菌酶的药物组合物及其应用 | |
| CN117815261B (zh) | 一种锯叶棕果实提取物及其软胶囊的医药新用途 | |
| CN120771134A (zh) | 一种燕麦特征功能组分在制备改善肠道健康产品中的应用 | |
| CN116139258A (zh) | 刺梨sod在制备用于预防或治疗肠道疾病食品或药物中的用途 | |
| Ogundepo et al. | The role of diosgenin in crohn’s disease | |
| Kierkus et al. | P525 Efficacy infliximab with immunomodulator and infliximab alone of maintenance therapy in children with Crohn's disease–multicenter randomized study | |
| Gorbatova et al. | THE IMPORTANCE OF BIOLOGICAL MARKERS IN THE PROGNOSIS OF ORAL LICHEN PLANUS | |
| CN120093735A (zh) | 一种肥胖抑制组合物、抑制剂及应用 | |
| Joshi et al. | Role of Vitamin-C, Vitamin-D and Zinc in Covid-19 Pandemic | |
| CN102000117B (zh) | 没食子提取物在制备抑制结肠癌细胞增殖的药物中的用途 | |
| Jing et al. | Intervention mechanism of Traditional Chinese medicine on the expression of TGF-β 1, IL-10 and MAdCAM-1 in ulcerative colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4Y | Validity of short term patent extended [from 6 to 10 years] |
Expiry date: 20210707 |
|
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |